Mutual funds increased holdings in 102 BSE smallcap stocks over four quarters, many delivering strong gains, including multiple multibaggers, highlighting institutional buying alongside significant price appreciation across select companies.Read More
Venture capital firm Peak XV Partners has exited Indian fintech One MobiKwik Systems. The firm sold its stake for over Rs 130 crore. This exit follows One MobiKwik’s significant milestone. The Reserve Bank of India approved its application for a Non-Banking Financial Company license. This approval allows the company to launch a new lending arm.Read More
Realty firm Embassy Office Parks REIT on Monday announced distribution of Rs 616 crore to unitholders for the March quarter, taking the total figures to Rs 2,396 crore during the last fiscal year.Read More
Blackstone-backed Bagmane Prime Office REIT is poised to hit the capital markets with its Rs 3,405 crore initial public offering (IPO), scheduled to open on May 5.Read More
HSBC trims India equity exposure to boost South Korea, citing Korea’s explosive earnings growth. While India’s earnings recovery is real but gradual, the bank maintains long-term conviction. Investors are advised to stay optimistic and focus on emerging sectors. Herald van der Linde, Chief Asia Equity Strategist at HSBC, explains why the downgrade is tactical, not...Read More
Ray Dalio warns of a shifting global order marked by rising geopolitical tensions, high debt, and stagflation risks, urging investors to diversify portfolios, hedge with gold, and prepare for long-term structural economic change.Read More
Varun Beverages shares extended gains after strong Q1 CY2026 results, with double-digit growth in profit, revenue, and volumes. Brokerages remain bullish, citing robust demand, margin resilience, and growth from international markets, while competition and input costs remain key monitorables for the company.Read More
Market expert Sandip Sabharwal maintains a constructive long-term outlook but stresses selectivity due to near-term risks like rising input costs and competition. He favors midcaps and selective smallcaps, seeing opportunities in consumer durables, while cautioning on financials and quick commerce. Large pharma deals require careful integration and valuation assessment.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
